Compounds > adenine
Page last updated: 2024-10-16

adenine and Infections, Lentivirus

adenine has been researched along with Infections, Lentivirus in 4 studies

Research Excerpts

ExcerptRelevanceReference
" Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application."5.39Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. ( Dinh, CT; Hendry, RM; Herold, BC; Kiser, PF; Martin, A; McNicholl, JM; Mesquita, PM; Nagaraja, U; Rastogi, R; Smith, JM; Srinivasan, P; Teller, RS, 2013)
" Variables that can be experimentally manipulated to address specific questions relevant to postexposure prophylaxis (PEP) include timing of initiation of treatment, duration of treatment, dosing regimen, virus strain, and virus inoculum."2.40Animal studies of prophylaxis. ( Black, RJ, 1997)
" Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application."1.39Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. ( Dinh, CT; Hendry, RM; Herold, BC; Kiser, PF; Martin, A; McNicholl, JM; Mesquita, PM; Nagaraja, U; Rastogi, R; Smith, JM; Srinivasan, P; Teller, RS, 2013)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Smith, JM2
Rastogi, R1
Teller, RS1
Srinivasan, P2
Mesquita, PM1
Nagaraja, U1
McNicholl, JM2
Hendry, RM1
Dinh, CT1
Martin, A1
Herold, BC2
Kiser, PF1
Dinh, C1
Zhang, J1
Pau, CP1
Lo, Y1
Teller, R1
Kiser, P1
Black, RJ1
Igarashi, T1
Brown, CR1
Endo, Y1
Buckler-White, A1
Plishka, R1
Bischofberger, N1
Hirsch, V1
Martin, MA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring[NCT02006264]Phase 130 participants (Actual)Interventional2013-11-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Grade 1 Genitourinary Events or Higher as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events

Grade 1 or higher Genitourinary events as defined by the DAIDS (Division of AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period judged to be related to study product (NCT02006264)
Timeframe: 14 days of vaginal ring use

InterventionAdverse events (Number)
TDF Intravaginal Ring7
Placebo Intravaginal Ring1

Grade 2 or Higher Adverse Events as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events

Grade 2 or higher systemic and local Adverse Events as defined by the Division of Aids (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period (NCT02006264)
Timeframe: 14 days of vaginal ring use

InterventionAdverse events (Number)
TDF Intravaginal Ring2
Placebo Intravaginal Ring0

TFV C-ave in Cervical Tissue

TFV (tenofovir) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use

Interventionng/mg (Median)
TDF Intravaginal Ring5.4

TFV-DP C-ave in Cervical Tissue

TFV-DP (tenofovir diphosphate) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use

Interventionfmol/mg (Median)
TDF Intravaginal Ring120

TDF and TFV Maximum Concentrations (C-max) in CVF Genital Secretions (ECX and VAG) and TFV Maximum Concentration in Plasma

TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) maximum concentrations (C-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)) and TFV maximum concentration (C-max) in plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal

Interventionng/mL (Median)
C-max CVF VAG TDFC-max CVF ECX TDFC-max CVF VAG TFVC-max CVF ECX TFVC-max Plasma TFV
TDF Intravaginal Ring24000021000091000850001.9

TDF and TFV Time to Maximum Concentrations (T-max) in CVF Genital Secretions (ECX and VAG), and TFV Time to Maximum Concentration in Plasma

TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) time to maximum concentrations (T-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)), and TFV time to maximum concentration in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal

Interventionh (Median)
T-max CVF VAG TDFT-max CVF ECX TDFT-max CVF VAG TFVT-max CVF ECX TFVT-max Plasma TFV
TDF Intravaginal Ring6514714

TDF AUC0-14 in CVF Genital Secretions (ECX and VAG), TFV AUC0-14 in CVF Genital Secretions (ECX and VAG), and TFV AUC0-14 in Plasma

TDF (tenofovir disoproxil fumarate) AUC0-14 (Area Under the Curve (concentration versus time) days 0-14) in Cervicovaginal Fluid (CVF) genital secretions (ectocervix (ECX) and vagina(VAG)), TFV AUC0-14 in CVF genital secretions (ECX and VAG), and TFV (tenofovir) AUC0-14 in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal

Interventionngxd/mL (Median)
AUC0-14 (days 0-14), CVF VAG TDFAUC0-14 (days 0-14), CVF ECX TDFAUC0-14 (days 0-14), CVF VAG TFVAUC0-14 (days 0-14), CVF ECX TFVAUC0-14 (days 0-14), Plasma TFV
TDF Intravaginal Ring2000000130000011000009700009.4

Reviews

1 review available for adenine and Infections, Lentivirus

ArticleYear
Animal studies of prophylaxis.
    The American journal of medicine, 1997, May-19, Volume: 102, Issue:5B

    Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Administration Schedule; Interferon-

1997

Other Studies

3 other studies available for adenine and Infections, Lentivirus

ArticleYear
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Oct-01, Volume: 110, Issue:40

    Topics: Adenine; Administration, Intravaginal; Animals; Delayed-Action Preparations; Drug Delivery Systems;

2013
Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use.
    Journal of medical primatology, 2014, Volume: 43, Issue:5

    Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Drug Delivery Systems; Female; HIV;

2014
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Jan-16, Volume: 98, Issue:2

    Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Chimera; Digestive System; Disease Progress

2001